Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Autoimmune Disorders

Free Subscription 01.06.2026 1 Am J Kidney Dis 1 Ann Neurol 3 BMC Neurol 2 Brain 1 Curr Opin Immunol 2 Intern Med 1 J Autoimmun 2 J Immunol 6 J Neuroimmunol 3 J Neurol 2 Kidney Int 6 Lancet 4 Mult Scler 4 Neurology 6 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Kidney Dis

1. WU J, Kim D, Guo L, Wang J, et al
   Hematuria Remission and Prognosis in IgA Nephropathy: A Post hoc Analysis of The TESTING Randomized Clinical Trial.
   Am J Kidney Dis. 2026 May 28:S0272-6386(26)00935.
   PubMed        
   
   

   
   Ann Neurol

2. MARMOLEJO L, Papi C, Milano C, Aguilar E, et al
   CSF-Compartmentalized Antibody Glycoprofiles in NMDAR Encephalitis Associate with Etiology and Functional Recovery.
   Ann Neurol. 2026;99:1468-1479.
   PubMed         Abstract available
   
   

   
   BMC Neurol

3. BAKR NM, Hashim NA, El-Eshmawy MA, El-Baz HA, et al
   Impact of genetic polymorphisms in the interleukin-18 and interleukin-21 genes on the risk and clinical outcomes of multiple sclerosis.
   BMC Neurol. 2026;26:355.
   PubMed         Abstract available
   
   
4. XU C, Zhang Y, Chen J
   Telitacicept as a potential therapeutic alternative in autoantibody-negative probable autoimmune encephalitis: a case report.
   BMC Neurol. 2026 May 27. doi: 10.1186/s12883-026-04995.
   PubMed         Abstract available
   
   
5. KANANI MM, Abolhassani S, Nazari F
   The role of health literacy in medication adherence among people living with multiple sclerosis: a cross-sectional study in Isfahan, Iran.
   BMC Neurol. 2026 May 25. doi: 10.1186/s12883-026-04985.
   PubMed         Abstract available
   
   

   
   Brain

6. TUR C
   High-efficacy therapy and progression independent of relapse and MRI activity in multiple sclerosis.
   Brain. 2026 May 28:awag175. doi: 10.1093.
   PubMed        
   
   
7. GRANBERG T
   The skull-meningeal axis: a new window into multiple sclerosis progression.
   Brain. 2026 May 28:awag177. doi: 10.1093.
   PubMed        
   
   

   
   Curr Opin Immunol

8. CAMERA M, Tremoli E, Lonati PA, Meroni PL, et al
   Novel mechanisms linking platelet activation to antiphospholipid syndrome.
   Curr Opin Immunol. 2026;101:102791.
   PubMed         Abstract available
   
   

   
   Intern Med

9. SATO T, Kobayashi J, Kuroda M, Aono K, et al
   Severe HDL-C Deficiency Caused by Acquired LCAT Deficiency: A Case Report with Lipidomic Profiling and Anti-LCAT Autoantibody Detection.
   Intern Med. 2026 May 23. doi: 10.2169/internalmedicine.7266.
   PubMed         Abstract available
   
   
10. YAMANISHI Y, Miyaue N, Ochi C, Ito Y, et al
    Coexistence of Parkinson's Disease and Myasthenia Gravis with Symptom Exacerbation Induced by Biperiden: A Case Report.
    Intern Med. 2026 May 23. doi: 10.2169/internalmedicine.7260.
    PubMed         Abstract available
    
    

    
    J Autoimmun

11. LI R, Li X, Zhu X, Liu S, et al
    Orelabrutinib for systemic lupus erythematosus: A randomised, double-blind, placebo-controlled study.
    J Autoimmun. 2026;161:103578.
    PubMed         Abstract available
    
    

    
    J Immunol

12. ROMO-TENA J, Sengupta S, Carmona-Rivera C, Nakabo S, et al
    Preconditioning determines engraftment and therapeutic efficacy of anti-CD19 CAR-T cells in murine lupus.
    J Immunol. 2026;215:vkag112.
    PubMed         Abstract available
    
    
13. AKBAR I, Arokia Doss PMI, Patel PU, Surury B, et al
    Myelin antigen-specific effector CD8+ T cells induce chronic CNS autoimmunity in a CD4+ T cell-dependent manner.
    J Immunol. 2026;215:vkag107.
    PubMed         Abstract available
    
    

    
    J Neuroimmunol

14. ZAMMAR K, Safan A, Abushalbak DJ, Daromar A, et al
    Monoclonal antibody efficacy in seropositive vs seronegative NMOSD: systematic review and meta-analysis.
    J Neuroimmunol. 2026;417:578945.
    PubMed         Abstract available
    
    
15. LI H, Zhang S, Shu Y, Zhao Y, et al
    Establishment of a passive-transfer mouse model of anti-NMDAR encephalitis and delineation of the PI3K-AKT-HIF-1alpha Axis in antibody-induced neuronal injury.
    J Neuroimmunol. 2026;417:578943.
    PubMed         Abstract available
    
    
16. KUMAR G, Allushi B, Quinn JL, Maria Z, et al
    BCL6 promotes CCR2-driven CNS infiltration of encephalitogenic Th17 cells.
    J Neuroimmunol. 2026;417:578937.
    PubMed         Abstract available
    
    
17. KOSEK S, Wiberg A, Persson B, Gabrysch K, et al
    Targeted proteomic profiling of serum and CSF reveals CASP-8 as a candidate biomarker in anti-NMDAR encephalitis.
    J Neuroimmunol. 2026;417:578927.
    PubMed         Abstract available
    
    
18. GOVINDARAJAN R
    Real-world experience with switching from intravenous immunoglobulin to subcutaneous efgartigimod PH20 in patients with chronic inflammatory demyelinating polyradiculoneuropathy: A case series.
    J Neuroimmunol. 2026;417:578925.
    PubMed         Abstract available
    
    
19. HANDA H, Uzawa A, Shibuya K, Kojima Y, et al
    Diagnosis of Lambert-Eaton myasthenic syndrome: Muscle fatigue with normal manual muscle testing, areflexia, and electrodiagnostic findings.
    J Neuroimmunol. 2026;417:578917.
    PubMed         Abstract available
    
    

    
    J Neurol

20. PEGORINI C, Cattaneo D, Meotti M, Baglio F, et al
    Artificial intelligence for gait and balance in neurological disorders: a scoping review of clinical applications and technologies.
    J Neurol. 2026;273:346.
    PubMed         Abstract available
    
    
21. MENG H, Qi Y, Zhang M, Wang X, et al
    (18)F-DPA714 PET in MRI-negative autoimmune encephalitis: a supportive approach to aiding neuroinflammation identification, disease severity correlation, and treatment response prediction.
    J Neurol. 2026;273:342.
    PubMed         Abstract available
    
    
22. RUBIN M, Preziosa P, Margoni M, Storelli L, et al
    Cerebrovascular risk factors impact on brain atrophy and DTI-ALPS decrease in neuromyelitis optica spectrum disorder.
    J Neurol. 2026;273:338.
    PubMed         Abstract available
    
    

    
    Kidney Int

23. FURIE R, Anders HJ, Bertsias G, Delgado A, et al
    A post hoc analysis of BLISS-LN found Belimumab plus mycophenolate mofetil improves kidney outcomes versus placebo plus mycophenolate mofetil in active lupus nephritis.
    Kidney Int. 2026 May 21:S0085-2538(26)00397-2. doi: 10.1016/j.kint.2026.
    PubMed         Abstract available
    
    
24. SHEN X, Shu C, Dong Y, Li J, et al
    Therapeutic Efficacy and Antigenicity of a Novel PEGylated IgA Protease in Preclinical Models of IgA Nephropathy.
    Kidney Int. 2026 May 22:S0085-2538(26)00401-1. doi: 10.1016/j.kint.2026.
    PubMed         Abstract available
    
    

    
    Lancet

25. GIOVANNONI G, Airas L, Bove R, Cutter GR, et al
    Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.
    Lancet. 2026;407:2195-2207.
    PubMed         Abstract available
    
    
26. HAUSER SL, Giovannoni G, Montalban X, Oh J, et al
    Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.
    Lancet. 2026;407:2180-2194.
    PubMed         Abstract available
    
    
27. CLOWSE MEB, Isenberg DA, Merrill JT, Dorner T, et al
    Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2026 May 29:S0140-6736(26)00691-4. doi: 10.1016/S0140-6736(26)00691.
    PubMed         Abstract available
    
    
28. VOLLENHOVEN RV
    Targeting CD40 with dapirolizumab pegol: a new treatment for systemic lupus erythematosus.
    Lancet. 2026 May 29:S0140-6736(26)01008-1. doi: 10.1016/S0140-6736(26)01008.
    PubMed        
    
    
29. SAMARASEKERA U
    Stephen Hauser: transforming treatment for multiple sclerosis.
    Lancet. 2026;407:2163.
    PubMed        
    
    
30. COCCO E
    Integrating peripheral immune control and brain health in the multiple sclerosis continuum.
    Lancet. 2026;407:2144-2146.
    PubMed        
    
    

    
    Mult Scler

31. BARBUTI E, Piervincenzi C, Baione V, Ojha A, et al
    Clinical, structural, and functional MRI features predicting PIRMA at 5-year follow-up in multiple sclerosis.
    Mult Scler. 2026 May 22:13524585261445318. doi: 10.1177/13524585261445318.
    PubMed         Abstract available
    
    
32. AMINI F, Everett K, Zhu F, Li P, et al
    Phenotyping healthcare use before pediatric-onset multiple sclerosis, including by sex and age: A matched cohort study.
    Mult Scler. 2026 May 22:13524585261445372. doi: 10.1177/13524585261445372.
    PubMed         Abstract available
    
    
33. RUIZ-ALGUERO M, Ahmed SM, Zhu F, Zhao Y, et al
    Prescription drug dispensations 15 years before multiple sclerosis onset: A matched cohort study, British Columbia, Canada.
    Mult Scler. 2026 May 27:13524585261450813. doi: 10.1177/13524585261450813.
    PubMed         Abstract available
    
    
34. CHANG G, Nasr Z, Schoeps VA, Virupakshaiah A, et al
    Adenotonsillectomy is associated with increased risk and disease activity in pediatric-onset multiple sclerosis.
    Mult Scler. 2026 May 29:13524585261444244. doi: 10.1177/13524585261444244.
    PubMed         Abstract available
    
    

    
    Neurology

35. SHARMIN S, Roos I, Labauge PM, Filippi M, et al
    Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability.
    Neurology. 2026;106:e218056.
    PubMed         Abstract available
    
    
36. LAULETTA A, Rossini E, Beretta F, Damato V, et al
    Comparative Study of Sporadic and Immune Checkpoint Inhibitor-Related Forms of Myasthenia Gravis-Myositis Overlap Syndrome.
    Neurology. 2026;106:e218081.
    PubMed         Abstract available
    
    
37. ROUX T, Lejeune FX, Casey R, Audoin B, et al
    French NOMADMUS Cohort Overview: Landscape Evolution of AQP4+NMOSD and MOGAD From 2010 to 2024.
    Neurology. 2026;106:e218073.
    PubMed         Abstract available
    
    
38. GOMBOLAY GY, Rubin JP
    Sometimes Kids Really Are Just Little Adults: Early Access to High-Efficacy Therapy Decreases Disability in Pediatric Multiple Sclerosis.
    Neurology. 2026;106:e218168.
    PubMed        
    
    

    
    PLoS One

39. XU M, Cheng Q, Xie Y, Chen X, et al
    Multi-omics profiling reveals epidermal growth factor as a potential biomarker and therapeutic target in lupus nephritis and ANCA-associated vasculitis with rapidly progressive glomerulonephritis.
    PLoS One. 2026;21:e0349307.
    PubMed         Abstract available
    
    
40. SRIMANAN W, Keokajee P, Sawangsribanterng S
    A preliminary cost-utility analysis of routine myasthenia gravis and thyroid dysfunction screening in acquired comitant Esotropia.
    PLoS One. 2026;21:e0350280.
    PubMed         Abstract available
    
    
41. GUALCO C, Grange E, Rotondi F, Salivetto M, et al
    Vocational rehabilitation for people with multiple sclerosis: A systematic scoping review of international evidence.
    PLoS One. 2026;21:e0350122.
    PubMed         Abstract available
    
    
42. HARUNA Y, Tagami M, Kurosaki R, Nishio M, et al
    Development and evaluation of AI model with deep learning for segmentation of extraocular muscles in thyroid eye disease.
    PLoS One. 2026;21:e0349074.
    PubMed         Abstract available
    
    
43. PICHI F, Jimenez YP, Belletti M, Alsuwaidi A, et al
    Retinal macrophage-like cell activation and ganglion cell layer thinning are associated with disability and MRI lesion burden in multiple sclerosis.
    PLoS One. 2026;21:e0349679.
    PubMed         Abstract available
    
    
44. DENG Y, Shang Y, Zhang Y, Li D, et al
    Inhibition of neutrophil infiltration and NETs formation ameliorates neuropsychiatric and renal dysfunction in MRL/lpr mice with lupus.
    PLoS One. 2026;21:e0348011.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum